In JAMS arbitration, CRA was retained by the Claimant regarding a dispute involving the breach of fiduciary duty by former employees of a clinical stage therapeutic company. CRA estimated the Claimant’s cash flows using contemporaneous Claimant’s financial data, colorectal cancer incidence rates and treatment prices, relevant clinical trial and generic market entry studies, and potentially comparable companies financials. Such information, along with qualitative information, was considered to estimate the Claimant’s risk-adjusted net present value. Claimant presented our valuation methodology and work product in its mediation, which CRA attended.
IP Literature Watch: March 2024
In this month’s IP Literature Watch we include an article analyzing four case studies of controversy over license design in open-source software and hardware...